Obesity and Dementia: High Blood Pressure Drives Risk, New Study Finds

**The Journal of Clinical Endocrinology & Metabolism (JCEM)** is the world's leading peer-reviewed journal dedicated to advancing clinical research in endocrinology, diabetes, and metabolism, published monthly by the Endocrine Society in partnership with Oxford University Press.[1][2][3][6] Launched in 1941, JCEM has evolved from its roots in early endocrinology publications—absorbing elements like the American Goiter Association's transactions—into a flagship platform for translational science spanning discovery to patient outcomes.[4][8] It covers pathophysiology, diagnosis, treatment of endocrine disorders, and metabolic insights into conditions like cardiovascular disease, cancer, and aging, featuring original research, mini-reviews, clinical trials, guidelines, and commentaries.[1][2] Key achievements include its status as the most-cited journal in clinical endocrinology, with a 2024 Impact Factor of 5.1, drawing submissions from global researchers and boasting readership across 200+ countries.[1][3][5][6] High-quality peer review ensures rigorous standards, earning Continuing Medical Education credits for reviewers and adherence to Committee on Publication Ethics principles.[3] Under Editor-in-Chief Paul M. Stewart, it emphasizes unbiased, timely manuscript handling.[1][3][4] Currently, JCEM thrives with open access options, format-neutral submissions, and tools boosting article discoverability, including Altmetric scores and special collections.[2][3][6] Its global impact is amplified by initiatives like free access for low- and middle-income countries via Research4Life and EIFL.[6] Backed by the Endocrine Society's 18,000+ members in 122 countries—the world's oldest hormone research organization—JCEM drives innovation at the intersection of biotech, pharma, and precision medicine, making breakthroughs accessible to clinicians and tech-driven health ventures.[2][6] For business and tech audiences, JC